NO20000411L - 4-amino-fenylalamin forbindelser som inhiberer leukocytt adhesjon mediert av VLA-4 - Google Patents
4-amino-fenylalamin forbindelser som inhiberer leukocytt adhesjon mediert av VLA-4Info
- Publication number
- NO20000411L NO20000411L NO20000411A NO20000411A NO20000411L NO 20000411 L NO20000411 L NO 20000411L NO 20000411 A NO20000411 A NO 20000411A NO 20000411 A NO20000411 A NO 20000411A NO 20000411 L NO20000411 L NO 20000411L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- vla
- leukocyte adhesion
- phenylalamine
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
Abstract
Det beskrives forbindelser som binder VLA-4. Enkelte av disse forbindelsene inhiberer også leukocytt-adhesjon, og særlig leukocytt-adhesjon mediert av VLA-4. Slike forbindelser er egnet ved behandlingen av inflammatoriske sykdommer i et pattedyr, f.eks. menneske, så som astma, Alzheimers sykdom, aterosklerose, AIDS-demens, diabetes, inflammatory bowel disease, reumatoid artritt, vevs-transplantasjon, tumormetastase og myokardiskemi. Forbindelsene kan også administreres for behandling av inflammatoriske hjernesykdommer, så som multippel sklerose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92035397A | 1997-07-31 | 1997-07-31 | |
PCT/US1998/015312 WO1999006434A1 (en) | 1997-07-31 | 1998-07-30 | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20000411D0 NO20000411D0 (no) | 2000-01-27 |
NO20000411L true NO20000411L (no) | 2000-03-28 |
Family
ID=25443597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20000411A NO20000411L (no) | 1997-07-31 | 2000-01-27 | 4-amino-fenylalamin forbindelser som inhiberer leukocytt adhesjon mediert av VLA-4 |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1001974B1 (no) |
JP (1) | JP2003517424A (no) |
KR (1) | KR20010022414A (no) |
CN (1) | CN1265674A (no) |
AR (1) | AR014903A1 (no) |
AT (1) | ATE327245T1 (no) |
AU (1) | AU8584698A (no) |
BR (1) | BR9812118A (no) |
CA (1) | CA2290750A1 (no) |
DE (1) | DE69834642T2 (no) |
HU (1) | HUP0004531A3 (no) |
IL (1) | IL133638A0 (no) |
NO (1) | NO20000411L (no) |
NZ (1) | NZ502580A (no) |
PL (1) | PL338413A1 (no) |
WO (1) | WO1999006434A1 (no) |
ZA (1) | ZA986837B (no) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6903075B1 (en) | 1997-05-29 | 2005-06-07 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
JP2002501518A (ja) * | 1997-05-30 | 2002-01-15 | セルテック セラピューティックス リミテッド | 抗炎症性チロシン誘導体 |
ES2206953T3 (es) | 1997-06-23 | 2004-05-16 | Tanabe Seiyaku Co., Ltd. | Inhibidores de la adherencia celular mediada por alfa 4-beta 1. |
US6197794B1 (en) * | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
US6555562B1 (en) | 1998-02-26 | 2003-04-29 | Celltech R&D Limited | Phenylalanine derivatives |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
AU3563799A (en) | 1998-04-16 | 1999-11-01 | Texas Biotechnology Corporation | Compounds that inhibit the binding of integrins to their receptors |
GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB9811969D0 (en) * | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
US6685617B1 (en) | 1998-06-23 | 2004-02-03 | Pharmacia & Upjohn Company | Inhibitors of α4β1 mediated cell adhesion |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
US6333340B1 (en) * | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821222D0 (en) | 1998-09-30 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
HUP0200155A3 (en) * | 1999-02-18 | 2005-04-28 | Hoffmann La Roche | Thioamide derivatives, pharmaceutical compositions containing them and their use |
US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
US6723711B2 (en) | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
PL354063A1 (en) * | 1999-08-13 | 2003-12-15 | Biogen, Inc.Biogen, Inc. | Cell adhesion inhibitors |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
KR20020067050A (ko) | 1999-12-28 | 2002-08-21 | 화이자 프로덕츠 인코포레이티드 | 염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제 |
WO2001079173A2 (en) | 2000-04-17 | 2001-10-25 | Celltech R & D Limited | Enamine derivatives as cell adhesion molecules |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
EP1301488A1 (en) | 2000-07-07 | 2003-04-16 | Celltech R&D Limited | Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists |
CA2417059A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
MY129000A (en) | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
MY140707A (en) | 2002-02-28 | 2010-01-15 | Mitsubishi Tanabe Pharma Corp | Process for preparing a phenylalanine derivative and intermediates thereof |
TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
MXPA05007823A (es) * | 2003-01-24 | 2005-10-18 | Elan Pharm Inc | Composicion y tratamiento de enfermedades desmielizantes y paralisis por administracion de agentes remielinizantes. |
JP2006513250A (ja) * | 2003-01-28 | 2006-04-20 | 中国科学院上海薬物研究所 | アラニン系化合物、その製造方法及び用途 |
US7196112B2 (en) | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
KR100646882B1 (ko) * | 2004-08-09 | 2006-11-23 | 엘지전자 주식회사 | 전기오븐레인지의 오븐부 배기구조 |
US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
NZ553202A (en) | 2004-08-19 | 2010-12-24 | Vertex Pharma | Modulators of muscarinic receptors |
WO2006022442A1 (ja) * | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
AU2005309365B2 (en) | 2004-11-29 | 2011-10-06 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
AU2006330866A1 (en) | 2005-12-22 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
CA2856037C (en) | 2005-12-28 | 2017-03-07 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
NZ570497A (en) | 2006-02-22 | 2011-09-30 | Vertex Pharma | Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors |
KR20080094964A (ko) | 2006-02-22 | 2008-10-27 | 버텍스 파마슈티칼스 인코포레이티드 | 무스카린성 수용체의 조절제 |
US7858790B2 (en) | 2006-06-29 | 2010-12-28 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
WO2008021375A2 (en) | 2006-08-15 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
WO2008021545A2 (en) | 2006-08-18 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
AU2008219007A1 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
EP2207549A1 (en) | 2007-10-03 | 2010-07-21 | Vertex Pharmceuticals Incorporated | Modulators of muscarinic receptors |
PL2288715T3 (pl) | 2008-04-11 | 2015-03-31 | Merrimack Pharmaceuticals Inc | Łączniki będące albuminą surowicy ludzkiej i ich koniugaty |
DE102009058289A1 (de) | 2009-12-04 | 2011-06-09 | Vladimir Volchkov | Viertaktmotor und Verfahren zu seinem Betrieb |
DE102009058290A1 (de) | 2009-12-04 | 2011-06-09 | Vladimir Volchkov | Viertaktmotor, Verfahren zu seinem Betrieb und Kraftstoffeinspritzverfahren |
DE102010008225A1 (de) | 2010-02-09 | 2011-08-11 | Volchkov, Vladimir, 71638 | Viertakt-Gegenkolbenmotor und Verfahren zu seinem Betrieb |
AU2019373245C1 (en) | 2018-10-30 | 2022-10-27 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4β7 integrin |
KR20240015737A (ko) | 2018-10-30 | 2024-02-05 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체 |
CA3115820A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995015973A1 (en) * | 1993-12-06 | 1995-06-15 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
AR016133A1 (es) * | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
-
1998
- 1998-07-30 PL PL98338413A patent/PL338413A1/xx unknown
- 1998-07-30 IL IL13363898A patent/IL133638A0/xx unknown
- 1998-07-30 AU AU85846/98A patent/AU8584698A/en not_active Abandoned
- 1998-07-30 WO PCT/US1998/015312 patent/WO1999006434A1/en active IP Right Grant
- 1998-07-30 KR KR1020007000994A patent/KR20010022414A/ko not_active Application Discontinuation
- 1998-07-30 CA CA002290750A patent/CA2290750A1/en not_active Abandoned
- 1998-07-30 NZ NZ502580A patent/NZ502580A/en unknown
- 1998-07-30 BR BR9812118-9A patent/BR9812118A/pt not_active Application Discontinuation
- 1998-07-30 AR ARP980103777A patent/AR014903A1/es unknown
- 1998-07-30 AT AT98937049T patent/ATE327245T1/de not_active IP Right Cessation
- 1998-07-30 ZA ZA9806837A patent/ZA986837B/xx unknown
- 1998-07-30 EP EP98937049A patent/EP1001974B1/en not_active Expired - Lifetime
- 1998-07-30 HU HU0004531A patent/HUP0004531A3/hu unknown
- 1998-07-30 CN CN98807763A patent/CN1265674A/zh active Pending
- 1998-07-30 DE DE69834642T patent/DE69834642T2/de not_active Expired - Fee Related
- 1998-07-30 JP JP2000505189A patent/JP2003517424A/ja active Pending
-
2000
- 2000-01-27 NO NO20000411A patent/NO20000411L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2290750A1 (en) | 1999-02-11 |
ATE327245T1 (de) | 2006-06-15 |
PL338413A1 (en) | 2000-11-06 |
EP1001974B1 (en) | 2006-05-24 |
AU8584698A (en) | 1999-02-22 |
DE69834642D1 (de) | 2006-06-29 |
DE69834642T2 (de) | 2007-05-03 |
JP2003517424A (ja) | 2003-05-27 |
ZA986837B (en) | 2000-05-02 |
KR20010022414A (ko) | 2001-03-15 |
AR014903A1 (es) | 2001-04-11 |
BR9812118A (pt) | 2000-07-18 |
EP1001974A1 (en) | 2000-05-24 |
NZ502580A (en) | 2001-06-29 |
HUP0004531A2 (hu) | 2001-04-28 |
IL133638A0 (en) | 2001-04-30 |
CN1265674A (zh) | 2000-09-06 |
HUP0004531A3 (en) | 2001-12-28 |
WO1999006434A1 (en) | 1999-02-11 |
NO20000411D0 (no) | 2000-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20000411L (no) | 4-amino-fenylalamin forbindelser som inhiberer leukocytt adhesjon mediert av VLA-4 | |
NO20000410L (no) | Dipeptid og beslektede forbindelser som inhiberer leukocytt adhesjon mediert av VLA-4 | |
NO20000450L (no) | Substituerte fenylalaninforbindelser som inhiberer leukocytt- adhesjon mediert av VLA-4 | |
NO20000414L (no) | Benzylforbindelser som inhiberer leukocytt adhesjon mediert av VLA-4 | |
NO20000451L (no) | Forbindelser som inhiberer leukocyttadhesjon mediert av VLA-4 | |
NO20000412L (no) | Dipeptidforbindelser som inhiberer leukocytt-adhesjon mediert av VLA-4 | |
NO20000452L (no) | Sulfonylerte dipeptidforbindelser som inhiberer leukocyttadhesjon mediert av VLA-4 | |
NO20000413L (no) | Karbamyloksyforbindelser som inhiberer leukocytt adhesjon mediert av VLA-4 | |
NO20082002L (no) | Pyrimidinylamidforbindelser som inhiberer leukocyttadhesjon mediert ved VLA-4 | |
NO20083743L (no) | Pyrimidinylsulfonamidforbindelser som inhiberer leukocyttadhesjon mediert av VLA-4 | |
NO20070216L (no) | Multivalente VLA-1 antagonister inneholdende polymerhalvdeler | |
MXPA01007335A (es) | Derivados de acilo los cuales tratan trastornos relacionados con alfa4 beta1 integrina y cd49d/cd29 (vla-4). | |
BR0308881A (pt) | Compostos heterocìclicos que inibem adesão leucocitária mediada por a4 integrinas | |
NO20045276L (no) | Heteroarylforbindelser som inhiberer leukocyttadhesjon formidlet ved alfa-4-integriner | |
WO2002008203A3 (en) | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4 | |
FI925986A (fi) | Slumpartat bio-oligomer bibliotek, ett foerfarande foer syntetisering avdet samt ett foerfarande foer anvaendning av det | |
NO965098L (no) | Perfluoralkylketoninhibitorer av elastase og fremgangsmåter for fremstilling av disse | |
DE602006020754D1 (de) | Carbamatverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren | |
DE60009883D1 (de) | Alpha-aminoessigsäure derivate als alpha 4 beta 7- rezeptor antagonisten | |
WO2002008201A3 (en) | Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4 | |
WO2005111020A3 (en) | Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4 | |
ATE370934T1 (de) | Substituierte dihydrophenanthridin-sulfonamide | |
WO2000043413A3 (en) | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4 | |
WO2004035606A3 (en) | Bace binding peptides and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |